Driven by excellence, focused on strategies for the longer term.

This is the crux of who we are. It is an articulation of precision in purpose, from the Firm’s beginnings to where we are today. Our collective eye is unerringly trained on tomorrow.

Deep sectoral expertise across services and industries.

Our insistence on strategic advisory exacts an in-depth understanding of and involvement with our clients’ businesses and industries. We engage not just individual businesses, but also contribute to the country’s legal and regulatory frameworks.

Personal commitment supported by experience and grit.

We commit early. We pull together internally for greater support. Every effort is sincere, every individual deeply dedicated to their task, their role, to the Firm.

Our undertakings for long-term impact are an organic extension of our purpose.

They are to employ our deep knowledge of the law beyond the business, the transaction, the deal. To use the opportunities and skills we possess, to reflect on the culture we’re creating. Individually and collectively, these are our efforts to help shape the thinking of our future generations, and arm them with strategies for true, sustainable growth.

Knowledge-sharing is intrinsic to equity and inclusivity.

This is a repository of thought leadership, deep insights and strong viewpoints, legal and other news and events and how they impact the industry and our clients.

Relevance is critical to growth. It necessitates a firm that is dynamic and responsive.

Amplifying intrinsic talent, sharpening skills, expanding knowledge, is vital to leading. It defines every aspect of how our firm functions and transacts. This is how we create new benchmarks and set industry standards.

  • Connect
May 09, 2023

Cairnhill CIPEF Limited and Cairnhill CGPE Limited, entities managed by Capital Group, in relation to the IPO of equity shares, by Mankind Pharma Limited

AZB & Partners recently advised Cairnhill CIPEF Limited and Cairnhill CGPE Limited, entities managed by Capital Group, in relation to the initial public offering (“IPO”) of equity shares of face value of INR 1 each (“Equity Shares”), by Mankind Pharma Limited (“Company”), which was undertaken by way of an offer for sale of Equity Shares by the selling shareholders, which aggregated to INR 43.26 billion. This deal is one of the largest public offerings by a domestic drug manufacturer in India since 2020.

The team advising the entities managed by Capital Group, comprised our Senior Partners, Darshika Kothari, Varoon Chandra and Agnik Bhattacharyya; Partner, Prerak Ved; Senior Associates, Rahul Aggarwal, Sneha Nagvekar and Alby Joseph; and Associates, Aratrika Choudhuri and Harsh Vardhan Singh.

AUTHORS & CONTRIBUTORS

TAGS

SHARE

Subscribe

DISCLAIMER

These are the views and opinions of the author(s) and do not necessarily reflect the views of the Firm. This article is intended for general information only and does not constitute legal or other advice and you acknowledge that there is no relationship (implied, legal or fiduciary) between you and the author/AZB. AZB does not claim that the article's content or information is accurate, correct or complete, and disclaims all liability for any loss or damage caused through error or omission.

RELATED READING

Deals

Bharti Hexacom Limited and the selling shareholder, Telecommunications Consultants India Limited, on its initial public offering, which was undertaken by way of an offer for sale by Telecommunications Consultants India Limited

Apr 16, 2024 | Capital Markets
Deals

Paytm E-commerce Private Limited (now rebranded as Pai Platforms) on launching their presence on the ONDC platform – an e-commerce platform fronted by the Government of India, touted to be the UPI equivalent of e-commerce in the near future

Apr 11, 2024 | Technology Media and Telecommunication
Deals

The Promoters of Appasamy Group (Appasamy Family) and Appasamy Associates on Warburg Pincus’ recent acquisition of stake in the Appasamy Group

Apr 11, 2024